Ahmed El-Sharkawy
Lobna Al Zaidan
Ahmed Malki- 1Human Molecular Genetics Laboratory, Institute of Genetics and Biophysics “A. Buzzati-Traverso” (IGB)-CNR, Naples, Italy
- 2Biomolecular Science Programme, Università Degli Studi Della Campania “Luigi Vanvitelli”, Naples, Italy
- 3Biomedical Science Department, College of Health Sciences, Qatar University, Doha, Qatar
The Epstein–Barr virus (EBV) is the first herpesvirus identified to be associated with human cancers known to infect the majority of the world population. EBV-associated malignancies are associated with a latent form of infection, and several of the EBV-encoded latent proteins are known to mediate cellular transformation. These include six nuclear antigens and three latent membrane proteins (LMPs). In lymphoid and epithelial tumors, viral latent gene expressions have distinct pattern. In both primary and metastatic tumors, the constant expression of latent membrane protein 2A (LMP2A) at the RNA level suggests that this protein is the key player in the EBV-associated tumorigenesis. While LMP2A contributing to the malignant transformation possibly by cooperating with the aberrant host genome. This can be done in part by dysregulating signaling pathways at multiple points, notably in the cell cycle and apoptotic pathways. Recent studies also have confirmed that LMP1 and LMP2 contribute to carcinoma progression and that this may reflect the combined effects of these proteins on activation of multiple signaling pathways. This review article aims to investigate the aforementioned EBV-encoded proteins that reveal established roles in tumor formation, with a greater emphasis on the oncogenic LMPs (LMP1 and LMP2A) and their roles in dysregulating signaling pathways. It also aims to provide a quick look on the six members of the EBV nuclear antigens and their roles in dysregulating apoptosis.
Introduction
It is currently known that viral infections are responsible for 15–20% of all human cancers (1). These oncogenic viruses have many complicated strategies that disrupt biological pathways in the infected host cells. The genetic material of these viruses undergoes several processes: replicating in harmony with the cell division of the infected host, escaping from immune surveillance, and inhibiting apoptosis (2). In addition, it increases the activities of telomerase enzyme resulting in immortality of the infected host cells (3, 4). Moreover, virus infected cells have an altered cell-to-cell adhesion properties facilitating further proliferation, transmission, and spreading of the virus particles to other areas of the body (5).
One of the best-studied example of these viruses are the herpesviruses which are prevalent in the animal kingdom. They are large double-stranded DNA viruses with a genome size of 100–200 kilobases (6). In humans, eight herpesviruses have been identified: herpes simplex virus 1 and 2 (HSV-1 and HSV-2) or human herpesvirus (HHV-1) and (HHV-2); varicella-zoster virus (VZV or HHV-3); Epstein–Barr virus (EBV or HHV-4); human cytomegalovirus (HCMV or HHV-5); human herpesviruses 6 and 7 (HHV-6 and HHV-7); and Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV-8) (6).
Epstein–Barr virus is a HHV that causes many human B cell lymphomas, including Burkitt lymphoma (BL), Hodgkin lymphoma (HL), diffuse large B cell lymphoma, and lymphoproliferative disease in immunocompromised hosts (7, 8). Tumors infected with EBV are largely composed of latently infected cells. In this stage, the virus is still in the nuclear episome form and is replicated by the DNA polymerase of the host cell (9). EBV-positive human lymphomas have many distinctive forms of viral latency, which differ in the number of genes expressed, of which only type III EBV latency converts primary B cells into long-term lymphoblastoid cell lines (LCLs) in vitro (9). However, this form of latency is the most immunogenic form and usually restricted to tumors of immunosuppressed patients. Latency III represents the most extensive form of latent infection and a variety of non-coding RNAs, as well as 10 EBV-encoded proteins are expressed in this stage. These are latent membrane proteins (LMP1, LMP2A, and LMP2B), EBV nuclear antigens (EBNA-1, EBNA-2, EBNAs-3A, -3B, -3C, and EBNA-LP), and the viral BCL-2 homolog, BHRF1. In addition, two non-coding RNAs (EBER1 and EBER2) and two families of microRNAs encoded within the BamHI A rightward transcripts (BARTs) and the BHRF1 locus (BHRF1 miRNAs), respectively (Table 1) (10–13). These products of EBV genes are expressed at different time points after EBV infection of B cells and leading finally to growth transformation Figure 1 (14).
Table 1. Epstein–Barr virus (EBV) gene expression and viral latency.
Figure 1. Epstein–Barr virus (EBV)-associated malignancies patterns of gene expression. Latency III EBV gene expression: found in in vitro transformed B cells into lymphoblastoid cell lines (LCLs); Latency I EBV gene expression: found in the majority (85%) of EBV-positive Burkitt lymphomas (BLs); Wp-restricted Latency: found in a minority (15%) of EBV-positive BLs (Wp-BL); and Latency II EBV gene expression: found in EBV-positive Hodgkin lymphoma (HL) as well as the EBV-associated epithelial malignancies, nasopharyngeal carcinoma (NPC), and gastric carcinoma (GC). Latent proteins [Epstein–Barr virus nuclear antigen (EBNA)1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP, BHRF1, latent membrane protein (LMP)1 and LMP2A/B] are shown in blue. Non-coding RNAs [Epstein–Barr encoded RNAs (EBERs), miR-BHRF1s, and miR-BamHI A rightward transcripts (BARTs)] are shown in red, and selected latent promoters (Cp, Wp, and Qp) are shown in green. Connecting lines denote splicing patterns, while blocks indicate exons. In Wp-BL, EBNA-LP is truncated due to a genomic deletion and is therefore denoted as t-EBNA-LP (14).
Both post-transplant lymphoproliferative disorder cells and LCLs produce all six Epstein–Barr virus nuclear antigens (EBNA) and three LMPs (15). These proteins are necessary for transforming B cells, as mutated viruses that lack EBNA1, EBNA2, EBNA-LP, or LMP1 show a huge reduction in their ability to transform B cells (16–20). However, whether these proteins are sufficient for B cell transformation remains unclear. Beside these proteins, EBV genome encodes many non-coding RNAs, including the Epstein–Barr encoded RNAs (EBERs), as well as 25 miRNAs and one small nucleolar RNA (21–25). miRNAs impair the translation and reduce the stability of mRNAs—that contain complementary sequences—by direct binding to them.
Recent reverse genetic analysis helped in identification that only five EBV oncoproteins and viral miRNAs are crucial for conversion of primary B-cells into continuously proliferating LCLs (26, 27). Recently it has been shown a cooperation functions between LMP1 and LMP2 toward contribution to progression of carcinomas reflected by their combined effects on activation of multiple signaling pathways (Figure 2) (28, 29).
Figure 2. Latent membrane proteins (LMPs) (1 and 2A) downstream signal transduction pathways (28).
In this review, we thought to shed lights on the EBV–LMPs (LMP1 and LMP2A) and Epstein–Barr Nuclear Antigens (EBNA-1, EBNA-2, EBNAs-3A, -3B, -3C, and EBNA-LP) due to their established roles in EBV persistence and latency. Moreover, we focused on their roles in different signal transduction pathways activation, which are critical for lymphoblastoid B-cell transformation, growth and survival, and therefore a potential therapeutic targets.
EBV-Latent Membrane Proteins
LMP1
The Epstein–Barr virus latent membrane protein 1 is expressed in many types of cancers, include gastric cancer, Burkitt’s lymphoma, and HL (28). It is also expressed in AIDS and post-transplant lymphomas (30). This protein has profound effects on cellular signaling pathways and growth. It modulates several processes, include migration, differentiation, and tumorigenesis (31, 32). Studies employs genetic deletion of recombinant viruses have shown that LMP1 is required as one of the LMPs for EBV-induced B-cell immortalization in vitro (29, 33). Significantly, LMP1 has an oncogenic function in non-lymphoid cells and it induces growth transformation in certain immortalized rodent fibroblast cells (34). In vitro studies have shown that heterologous expression of LMP1 lead to the loss of anchorage dependence, increased invasive capacity and inhibition of terminal differentiation in cancer cell lines (31).
Latent membrane protein 1 is an integral membrane protein with a molecular weight of 66 kDa. It consists of a short amino acid cytoplasmic N-terminus (amino acids 1–23), six transmembrane spanning regions (amino acids 24–186), and a large 200 amino acid cytoplasmic C-terminal tail (amino acid 187–386). The LMP1 transmembrane domains mediate homotypic aggregation, lipid raft association, and ligand-independent signaling from two cytoplasmic tail domains known as transformation effect site 1 (TES1) and TES2, or C-terminal activation region 1 (CTAR1) and CTAR2 (19, 35) C-terminal region contains three distinct functional domains: C-terminal activating regions 1, 2, and 3 (CTAR1, CTAR2, and CTAR3).
C-terminal activating region 1 and 2 (CTAR1 and CTAR2) are two activating regions located within the C-terminus of LMP1. CTAR1 (amino acids 186–231) is located proximal to the membrane and it is essential in primary B cells transformation by EBV. CTAR2 is located at the end of C-terminus (amino acids 351–386) and it is important for the long-term growth of EBV-positive primary B cells (36, 37). LMP1 activates many signaling pathways, include nuclear factor kB (NF-kB), c-Jun N-terminal kinase (JNK)–AP-1, p38/mitogen-activated protein kinase (MAPK), and Janus kinase (JAK)–signal transducers and activators of transcription (STAT) (Figure 3) (38–42).
Figure 3. Molecular interactions and signaling pathways engaged by LMP1 in the carcinogenesis of nasopharyngeal carcinomas (NPCs). LMP1 C-terminal activation region 1 (CTAR1) regulates NIK/IKKs activation and then phosphorylates IκBα, thus activating NF-κB through TNFR-associated factor (TRAF)1, TRAF2, and TRAF3; while CTAR2 activates NF-κB through tumor necrosis factor receptor-associated death domain (TRADD) and TRAF2. Active NF-κB induces the cell immortalization via the upregulation of the telomerase activity through the translocation of hTERT protein bound to NF-κB, blocks the cell apoptosis via the upregulation of the survivin activity, and promotes the cell proliferation via regulating survivin, CyclinD1, CyclinE and EGFR signaling, etc. Also, LMP1 can increase the serine phosphorylation level of Annexin A2 by activating the PKC signaling pathway, which can promote the cell proliferation. LMP1 CTAR2 triggers AP-1 signaling cascade by activating ERK, P38, and the c-Jun N-terminal kinases (JNKs), members of the stress-activated group of MAP kinases, via the binding with TRADD/TRAF2 complex. Active AP-1 upregulates the expression of MMP9 and mediates invasion and metastasis of NPC cells. LMP1 CTAR3 between CTAR1 and CTAR2 triggers the Janus kinase (JAK3)/signal transducers and activators of transcription (STAT) signaling pathway, which can enhance VEGF transcription and expression, thereby promoting invasion and metastasis of NPC cells (42).
The first important indication of the role of LMP1 in abnormal cell signaling was the activation of the NF-kB transcription factor (Figure 4) (43). NF-kB can be activated independently by both CTAR1 and CTAR2 (38). LMP1 mutant deletion studies confirmed that CTAR2 interacts with the tumor necrosis factor receptor-associated death domain (TRADD) protein and this interaction accounts for most (70–80%) of the LMP1-mediated NF-kB activation (44). TRADD normally mediates NF-kB activation and signaling from aggregated tumor necrosis factor receptor I (TNFR-I). LMP1 interaction with TRADD is mediated by the last eight amino acids of LMP1. However, these amino acids do not define the entire activation site (44). CTAR1 define the remaining (20–30%) of NF-kB activation by LMP1, specifically the P204xQ206xT208 motif which interacts with a number of the TNFR-associated factors (TRAFs) (45–47). The cytoplasmic tails of other TNFR members, including CD30 and CD40 are also contains the PxQxT TRAF binding motif.
Figure 4. LMP1-mediated activation of nuclear factor kB pathway (43).
Latent membrane protein 1 also activates JNK cascade (known as stress-activated protein kinase) (48). This pathway ends with the activation of the AP-1. LMP1 transient transfection studies suggest that CTAR2 is the only domain that induces the expression of the transcription factor AP-1 (49). Stimulation of CD40, TNFR-I, and TNFR-II with an appropriate ligand results in JNK activation which is mediated via a TRAF2-dependent pathway. Although both NF-kB and JNK pathways looks similar, LMP1-mediated activation of NF-kB and JNK pathways can be dissociated. Eliopoulos et al. showed that usage of a constitutively active mutated IkappaBα to inhibit the NF-kB pathway did not impair JNK signaling, whereas expression of a negative stress-enhanced kinase (c-Jun N-terminal kinase kinase) blocked the JNK signaling mediated by LMP1 but not NF-kB signaling (50).
Janus kinase 3 activation is mediated by a proline rich sequence within the 33 bp repeat of C-terminus of LMP1 and a surrounding sequence between CTAR1 and CTAR2 (40). This proline rich sequence has been tentatively referred to as CTAR3. The expression of the genes encoding LMP1 and JAK3 in 293 cells leads to enhanced JAK3 tyrosine phosphorylation and leads finally to the activation of STAT transcription (STAT1 and STAT3). LMP1-mediated activation of JAK/STAT pathway has a rapid kinetics giving rise to the fact that this pathway may precedes both NF-kB and JNK activation and might predisposes the cell to these later signals (51).
Latent membrane protein 1 also activates P38/MAPK pathway and the corresponding transcription factor ATF2. Studies employed C-terminal mutants of LMP1 have shown that CTAR1 and CTAR2 regions are important in activating p38 pathway (40). Specific inhibitors of NF-kB and P38/MAPK pathways were used to determine the relation between these two pathways. When an inhibitor of NF-kB activation was used, the activation of p38 was not impaired. Also, the use of an inhibitor of p38 did not affect the binding activity of NF-kB. These results suggested that LMP1 activates p38/MAPK and NF-kB pathways in an independent way. However, using non-functional mutant of TRAF2 to inactivate TRAF2 blocked both pathways suggesting that the two pathways diverge downstream of TRAF2 (40). LMP1 aggregation within the plasma membrane is a prerequisite for signaling irrespective of the LMP1-mediated signaling pathways. This aggregation is a transmembrane domains intrinsic property (44). LMP1 differs from TNFR family in that LMP1 serves as a constitutively activated receptor; therefore, requires no extracellular ligand binding. Chimeric molecules-based experiments using extracellular and transmembrane domains of CD2, CD4, or the nerve growth factor receptor with the cytoplasmic C-terminus of LMP1, proved that LMP1 signaling only occurred when chimera aggregation occurred via either ligand binding or antibody induced aggregation (44, 52). On the other hand, when the CD40 cytoplasmic tail linked to the N-terminal and transmembrane tails of LMP1, it became constitutively activated (53, 54).
Latent membrane protein 1 has the ability to transform MDCK cells by promoting an epithelial to mesenchymal transition (EMT) (54). In this cell line, the transcriptional repressor Twist is responsible for this phenomenon (55). LMP1 has been also shown to induce EMT in other epithelial cell lines, including breast (56), lung (57), and nasopharyngeal (54, 58–60). Horikawa et al. showed that overexpression of the transcriptional repressor snail is linked to LMP1 expression in NPC biopsies (55). This study showed also that EMT is induced by expression of LMP1 in a Snail-dependent mechanism. In a recent study conducted by Zuo et al. in NPC, they found that cadherin 6 is activated by LMP1 to mediate EMT and metastasis by switching from E-cadherin to K-cadherin (cadherin 6) (61). Morris et al. showed that LMP1 is able to induce EMT via its CTAR1 domain in MDCK cells (62). They used pharmacological inhibitors to inhibit ERK–MAPK, SFK, phosphotidylinositol 3-kinase (PI3-K), and TGFβ. They found that ERK–MAPK, SFK and PI3-K, but not TGFβ have critical roles in LMP1-mediated EMT. Ligation of β1 integrins with its cognate ligand, fibronectin was mandatory for ERK–MAPK and FAK phosphorylation by LMP1 (62).
In a recent study conducted by Liu et al. (63), they have showed that the γ-herpesvirus EBV blocks necroptosis in EBV-infected human nasopharyngeal epithelial cells and nasopharyngeal carcinoma (NPC) cells. In this study, LMP1 inhibit necroptosis independently from RIP homotypic interaction motif (RHIM) signaling competition as it lacks RHIM domain. CTAR of LMP1 interacts directly with both RIPK1&3. Importantly, LMP1 has the ability to modulate the post-translational modification of the two receptor-interacting proteins. In addition, LMP1 induces a switch from cell death by necroptosis to survival through promotion of K63-polyubiquitinated RIPK1, suppression of RIPK1 protein expression, and inhibition of K63-polyubiquitinated RIPK3. The authors have introduced an evidence on the ability of LMP1 to interrupt the initiation process of necroptosis before necrosome formation and hence suppression of necroptosis by EBV (Figure 5) (63).
Figure 5. Epstein–Barr virus (EBV)–LMP1 regulates T/S/Z-induced necroptosis. EBV–LMP1 (−) cells stimulated with T/S/Z undergo necroptosis through RIPK1–RIPK3 signaling. However, EBV–LMP1 (+) cells can survive under this stimulation. On the one hand, LMP1 interacts directly with both RIPK1 and RIPK3 through its C-terminal activation region. On the one hand, LMP1 promotes K63-linked polyubiquitination of RIPK1 and suppresses the protein expression while inhibiting K63-linked polyubiquitination of RIPK3. These effects contribute to the activation of NF-κB and disruption of necrosome formation, collectively switching cell fate from death to survival (63).
Latent Membrane Protein 2A (LMP2A)
Latent membrane protein 2A role in malignancy remains an enigma. In NPC, LMP2A expressed at both the RNA and the protein levels (64). Also, LMP2-specific antibodies were detected in sera of NPC patients (65). Moreover, LMP2A expression is consistently detected in Hodgkin’s lymphoma and NPC tissues (66, 67). Based on these findings, LMP2A may plays specific roles in malignancy (68). Despite earlier genetic studies stated that both LMP2A and LMP2B are not essential for the transformation of B cells in vitro (69, 70). Another study showed that LMP2A transforming feature presents only in the immortalized epithelial cell line, but not in normal epidermal cells (71). It also presented that LMP2A expression-associated transformation properties manifests only in certain cellular contexts and generally are subtler (72). LMP2A—according to another study—is also important for growth transformation of germinal center B cells. These B cells have deleterious somatic hypermutations in their immunoglobulin genes and therefore, they do not express genuine B cell receptor (BCR). The study suggested that LMP2A has strong antiapoptotic and/or transforming features. In certain B cells, they function as an indispensable BCR mimics as in Hodgkin’s lymphoma (73). In the following sections, various signaling pathways and involvement in viral latency and malignant transformation induced by LMP2 is covered (Figure 6).
Figure 6. A schematic diagram showing the signaling pathways engaged by the LMP2A gene. The N terminal domain of LMP2A prevents B cell receptor (BCR) signaling by recruiting Nedd4-like ubiquitin-protein ligases and B-cell signaling molecules, leading to the degradation of LMP2A and its associated molecules in a ubiquitin-dependent manner. LMP2A also provides a survival signal to BCR-negative B-cells through the activation of the Ras/phosphotidylinositol 3-kinase (PI3-K)/Akt pathway. Activating this pathway induces the transcription of anti-apototic genes, the expression of which is controlled by NF-κ B. Notch signaling regulates various cellular processes including cell survival and proliferation. In LMP2A-expressing splenic B cells, Notch activation is reported. Notch signaling is closely related to the pathogenesis of Hodgkin lymphoma (HL). LMP2A perturbs the turnover of β-catenin and other proteins that are involved in Wnt signaling. β-catenin is stabilized and activated by LMP2A through PI3-K/Akt activation, which inhibits glycogen synthase kinase-3β (GSK-3β). The association of LMP2A with mitogen-activated protein kinase (MAPK) was implicated in the development of B-cell malignancy while the activation of MAPK was not observed in LMP2A-expressing epithelial cells. The multiple cysteine motifs within the C-terminal of LMP2A are required for LMP2A palmitoylation. Studies of the proposed palmitoylation are required for LMP2A-mediated survival signal and function as they regulate the protein interaction or localization required for LMP2A-mediated cell survival.
BCR Blockade and Ubiquitin-Mediated Pathway
Latent membrane protein 2A expression interferes with BCR signaling and function. According to previous studies, LMP2A low expression did not inhibit Ig rearrangement or BCR expression. It also did not inhibit the differentiation of normal B cells into follicular and marginal zone B cells. On the contrary, the high expression of LMP2A inhibited BCR expression and caused B-1 differentiation in bone marrow and other peripheral lymphoid organs (74–76). LMP2A negatively regulates signaling of BCR in two ways: excluding BCR from lipid rafts and targeting the Src family members of the Lyn and Syk protein tyrosine kinases marking them for degradation by ubiquitin pathway (77, 78). The BCR signal transduction blockade is achieved by either sequestering PTK away from BCR or PTK degradation by ubiquitin (79–81). In B-cell signaling, Itchy (Nedd4 ubiquitin ligase) downregulates LMP2A activity. In epithelial cells, β-catenin is activated and stabilized by LMP2A through PI3-K and Akt activation, which suppresses glycogen synthase kinase-3β (GSK-3β) (82). GSK-3β is in turn tightly regulated by Wnt signaling (83). Further studies are needed to determine the precise mechanisms by which LMP2A alters these signaling pathways during viral latency and malignant transformation.
MAPK Pathway
Mitogen-activated protein kinase family consists of three pathways, namely ERK/MAPK, JNK/MAPK, and p38/MAPK.
The MAPK signaling pathways are involved in different fundamental events such as proliferation, differentiation, apoptosis, and migration under normal conditions (84, 85). Abnormal regulation of these pathways leads to carcinogenesis. LMP2A activates MAPK signaling in various EBV-infected cell lines according to several evidences in vitro (86–88). For example, one study on lymphoblastoid B-cell lines and BL cell lines suggested that LMP2A activates ERK/MAPK (88). Another study employed LMP2A transgenic mice stated that the continuous activation of ERK/MAPK and PI3-K/Akt pathways leads to proliferation and survival (89). c-Jun is a crucial downstream effector of the JNK/MAPK pathway. It is induced as an early factor under mitogen stimulation and it is playing a crucial rule in cell growth (90, 91). Moreover, it is a potent inhibitor of differentiation. In organic raft cultures, LMP2A is able to transform and inhibit keratinocytes differentiation (92–94). These observations link LMP2A to JNK/MAPK. According to microarray studies, alterations of gene transcription of several MAPK-related molecules are induced by LMP2A, including upregulation of Ras, its homolog Ras GTPase-activating protein-binding protein 1, MAPK2K1, MAPK2K2, and the suppression of Ras suppressor protein (88). Activated Ras cooperates with c-Jun for effective transformation (95, 96). The exact mechanism and molecular interaction of LMP2A in MAPK signaling remains unclear. In addition, our picture of the involvement of LMP2A in MAPK signaling derived from in vitro studies on different cell lines but there are no sufficient in vivo studies to support the connection between LMP2A and MAPK signaling.
The PI3-K/AKT Pathway
Phosphotidylinositol 3-kinase/Akt signaling pathway has an important role in transformation, antiapoptotic properties, adhesion, and invasion (97–101). Numerous studies have suggested that LMP2A activates PI3-K/Akt signaling which leads to cell growth enhancements and antiapoptotic effects in B-cells, lymphoma, gastric carcinoma (GC), and epithelial cells (73, 102, 103). When LY294002 is used as an inhibitor of PI3-K, it resulted in the inhibition of colony formation induced by LMP2A in soft agar. This phenomenon indicates that activation of PI3-K is critical for anchorage-independent growth of epithelial cells (104, 105). Treatment of B-cells derived from LMP2A transgenic mice with specific inhibitors of Ras, PI3-K, and Akt made these cells very sensitive to apoptosis. These results suggest that LMP2A activates Ras followed by the PI3-K/Akt pathways, ending in B-cell survival (104). In cell lines of human Burkett’s lymphoma and GC, usage of PI-3K inhibitors blocked the LMP2A-dependent apoptotic effects. This demonstrates that the LMP2A anti apoptotic effects depend on the PI3-k signaling pathway (105).
TGF-β1 induces apoptosis by activating caspases (106–109). TGF-β1-induced caspase activity and apoptosis is inhibited by LMP2A through activation of PI3-K/Akt pathway via Akt phosphorylation at its serine residue (105, 110). This is supported by increased level of activated Ras and Bcl-XL expression resulted in suppression of B-cell apoptosis (73). Integrin is the other pathway regulated by LMP2A-associated PI3-K/Akt. Integrin-dependent PI3-K activation leads to invasive and adhesive phenotypes, and therefore the protection of apoptosis (101, 111). PI3-K/Akt pathway activation plays an important role in EBV-associated malignancies. It maintains EBV persistence and latency but not cell transformation (102, 103). The aggressive tumorigenicity of epithelial cells is maintained due to the activation of Ras/PI3-K/Akt by LMP2A, alongside other genetic changes (103). The regulation of this pathway and its differential expression in different types of EBV-induced tumors have also yet to be discovered.
The NF-κB and STAT Pathway
Signal transducers and activators of transcription and NK-κB pathways constitutive activation occur in malignancies, commonly due to genetic or autocrine/paracrine alteration (74, 112). NF-kB activation in epithelial cells induces production of IL-6 and activates STAT (74, 113) which results in cell growth and survival. Moreover, it mediates inflammatory responses through induction of cytokines and chemokines production. This results in the stimulation of anti-tumor activity via the recruitment and activation of immune cells (113). Altering the balance between the tumorigenesis and the anti-tumor immune response in NF-kB pathway results in tumor development (74).
In human carcinoma cell lines infected by EBV, LMP2A downregulates the STAT and NF-kB pathways in vitro. This fact was tested by using wild-type (wt) recombinant EBV (rEBV) and mutant rEBV, in which the LMP2A gene is deleted (rEBV-2A) (114). The results showed that the transient expression of LMP2A in LMP2A-deficient carcinoma cells suppressed LMP1 expression, IL-6 secretion, STAT, and NF-kB activities. On the contrary, the downregulation of LMP2A resulted in the induction of LMP1 (114).
Nuclear factor kB pathway regulates the production of IL-6 (113). In rEBV HONE-1 cells, transfection of a recombinant adenovirus expressing mutant IkBα and the luciferase reporter showed that IL-6 promoter activity was noticeably decreased (114). These results suggested that LMP2A has an important role in modulating STAT pathways and in modulating LMP1 expression indirectly through NF-kB activity in epithelial cells (114). Both STAT and NF-kB contributes to various cancer phenotypes in EBV-associated malignancies. For example, NF-kB suppression induces epidermal hyperplasia which ends in developing the undifferentiated tumor; NPC (115). Akt also positively regulates NF-kB which leads to an increased level of Bcl-xL in B-cells, ensuring an antiapoptotic effect and cell survival (116).
EBV Nuclear Antigens
Epstein–Barr Nuclear Antigen 1
Epstein–Barr nuclear antigen 1 is essential for viral DNA replication and episome maintenance during cellular replication at latent stages in infected cells. Besides, it is the only protein that expressed in all EBV-associated tumors (105, 117–120). It has no enzymatic activity and it is not clear how it initiates and maintains EBV genome (117–119). It has been reported that EBNA1 is associated with the survival of Burkitt’s lymphoma cells and response to DNA damage in NPC. A possible mechanism is modulating of ROS content through regulation of nicotinamide adenine dinucleotide phosphate oxidase enzymes (121–123). Additional studies have reported that EBNA1 contribute to gastric cancer development through loss of promyelocytic leukemia nuclear bodies (123, 124).
DNA replication and episome maintenance functions of EBNA1 are due to its ability to bind to certain elements of DNA within the EBV origin of plasmid replication (OriP). EBNA1 requires the family of repeats (FR), which composed of 20 tandems 30 bp repeats to make the metaphase chromosome tethering and transcriptional enhancer activities (117, 118, 124, 125). Away ~1 kb from the FR is located the dyad of symmetry, which composed of four EBNA1 binding sites and enables EBNA1 to initiate DNA replication (117, 118, 124, 125). EBNA1 is able to interact with both elements simultaneously through a DNA looping mechanism (126–128). The binding of EBNA1 to OriP is critical for replication and maintenance of episome. EBNA-1 reportedly binds and regulates the promoters of many other cellular genes but the functional consequences and implications of these interactions for cell survival are not yet fully elucidated (128–132).
EBNA-2 and EBNA-LP
Following EBV infection of B cells, EBNA-2 and EBNA-LP are the first proteins to be expressed. EBNA2 expression is essential for B cell transformation (133). EBNA2 is a functional mimic of cellular Notch (133–135). Also, it has RBP-Jκ-mediated pleiotropic effects on chromatin organization and gene regulation which makes EBNA2 responsible for starting cell cycle (136–139). EBNA2 can directly bind and inhibit Nur77 (140, 141). Nur77 is an orphan nuclear receptor that binds and modulates the functions of several pro-survival BCL-2 family members (142). Moreover, expression of EBNA2 was shown to decrease the expression of BIK, the BCL-2 family death inducer (143). It was also shown that EBNA2 expression upregulates BFL-1/A1 (pro-survival BCL-2 family protein) at mRNA level via binding to RBP-Jκ/CBF1 (144). Recently, EBNA2 also contributes to MYC activation through long-range interaction (145). MYC has an opposing function as it can both increase proliferation and sensitize cells to apoptosis (146). Another nuclear antigen essential in B cell transformation is EBNA-LP (18, 147–149). It acts as a transcriptional coactivator of EBNA2 (16) and has few survival functions attributed to it in the context of LCLs. It has been reported that EBNA-LP can bind to Fte-1/S3a, which contributes to cell survival by interacting with PARP (150). However, another study found that in a yeast 2-hybrid system, EBNA-LP could interact with p14ARF and colocalized with p14ARF and p53 transcripts in LCLs (151). Additionally, in COS-7 (the primate kidney cell line) EBNA-LP has also been reported to interact with BCL-2 in the presence of HAX-1 in pull down experiments using glutathione S-transferase fusion proteins (151). Therefore, EBNA-LP seems to have survival functions in transformation which merit further investigations.
EBNA-3A, -3B, and -3C
The EBNA-3s (3A, 3B, and 3C) are a family of three large proteins, which function as regulators of virus and host cell transcription. They likely arose by gene duplication. These proteins, like EBNA-2 don’t bind DNA directly, but interact with transcription factors, such as RBP-Jk (for which all four EBNAs compete) to transactivate or repress gene expression (152). They show structural similarity; despite they share less than 30% amino acid composition (153, 154). In addition, they overlap in some of the loci and processes they regulate. Some studies have shown that only EBNA-3C is essential for B cell transformation, although when B cells infected with EBNA-3A-lacking viruses, they displayed growth impairment and quickly undergo apoptosis (155–157). On the contrary, EBNA-3B is essential for the transformation of B cells. In one study, LCLs generated with an EBNA-3B knockout (KO) virus showed high resistance to apoptosis compared to those produced with wt EBV (158, 159). Analysis of cells infected with EBNA-3 KO or estrogen-inducible EBNA-3 proteins conditional viruses showed that EBNA-3A and -3C cooperate to downregulate-through epigenetic silencing- the tumor suppressors p16INK4a and p14ARF (155, 156, 160–163) as well as downregulate the apoptosis inducing, BH3-only protein BIM. Moreover, EBNA-3C can interact with p53 as well as binding and stabilizing its regulators, ING4, ING5, MDM2, and Gemin3 (164–167). The EBNA3 proteins have the ability to regulate many genes up to 50 kb away from transcriptional start sites (TSS) (164, 168) despite EBNA-3A and -3C downregulate BIM and p14ARF at TSS through epigenetic silencing (156, 160–163, 169, 170). The EBNA-3 proteins have been estimated to collectively bind to more than 7,000 sites on the cellular genome. Therefore, extensive studies are needed to unravel many other cell survival genes regulated by the EBNA3s.
Conclusion
Further studies both in vivo and in vitro are required to elucidate the molecular crosstalk between EBV transformed tumor cells and the tumor microenvironment. These studies are essential to define the precise mechanisms in EBV-induced oncogenesis, and to enable further insights into EBV-associated malignancies. Moreover, more studies are needed to unravel the roles of these oncoproteins in dysregulating other forms of cell death like necroptosis which could serves as a potential alternative strategy of programmed cell death to apoptosis, hence a possible therapeutic target.
Author Contributions
AM designed the topics and contributed in writing. AE-S designed the topics and wrote the entire manuscript. LZ contributed in writing and reviewed the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding
AE-S has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 665403.
References
1. Jha HC, Banerjee S, Robertson ES. The role of gamma-herpesviruses in cancer pathogenesis. Pathogens (2016) 5(1):18. doi:10.3390/pathogens5010018
2. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 10(12):878–89. doi:10.1038/nrc2961
3. Morales Sánchez A, Fuentes Pananá EM. Human viruses and cancer. Viruses (2014) 6(10):4047–79. doi:10.3390/v6104047
4. Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G, et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol (2008) 82:10175–87. doi:10.1128/JVI.00321-08
5. Mui UN, Haley CT, Tyring SK. Viral oncology: molecular biology and pathogenesis. J Clin Med (2017) 6(12):111. doi:10.3390/jcm6120111
6. Damania B. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol (2004) 2:656–68. doi:10.1038/nrmicro958
7. Vereide D, Sugden B. Insights into the evolution of lymphomas induced by Epstein-Barr virus. Adv Cancer Res (2010) 108:1–19. doi:10.1016/B978-0-12-380888-2.00001-7
8. Vereide DT, Sugden B. Lymphomas differ in their dependence on Epstein-Barr virus. Blood (2011) 117:1977–85. doi:10.1182/blood-2010-05-285791
9. Thorley Lawson DA. EBV persistence -introducing the virus. Curr Top Microbiol Immunol (2015) 390(Pt 1):151–209. doi:10.1007/978-3-319-22822-8_8
10. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, et al. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis. PLoS Pathog (2009) 5:e1000341. doi:10.1371/journal.ppat.1000341
11. Xing L, Kieff E. Epstein-Barr virus BHRF1 micro and stable RNAs during latency III and after induction of replication. J Virol (2007) 81:9967–75. doi:10.1128/JVI.02244-06
12. Amoroso R, Fitzsimmons L, Thomas WA, Kelly GL, Rowe M, Bell AI. Quantitative studies of Epstein-Barr virus encoded microRNAs provide novel insights into their regulation. J Virol (2011) 85:996–1010. doi:10.1128/JVI.01528-10
13. Price A, Luftig M. Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. Adv Virus Res (2014) 88:279–313. doi:10.1016/B978-0-12-800098-4.00006-4
14. Fitzsimmons L, Kelly GL. EBV and apoptosis: the viral master regulator of cell fate. Viruses (2017) 9(11):339. doi:10.3390/v9110339
15. Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res (2014) 58(2-3):268–76. doi:10.1007/s12026-014-8496-1
16. Hammerschmidt W, Sudgen B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B-lymphocytes. Nature (1989) 340:393–7. doi:10.1038/340393a0
17. Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 86:9558–62. doi:10.1073/pnas.86.23.9558
18. Mannick JB, Cohen JI, Birkenbach M, Marchini A, Kieff E. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 65:6826–37.
19. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A (1993) 90:9150–4. doi:10.1073/pnas.90.19.9150
20. Humme S, Reisbach G, Feederle R, Delecluse HJ, Bousset K, Hammerschmidt W, et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousand fold. Proc Natl Acad Sci U S A (2003) 100:10989–94. doi:10.1073/pnas.1832776100
21. Lerner MR, Andrews NC, Miller G, Steitz JA. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1981) 78:805–9. doi:10.1073/pnas.78.2.805
22. Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, et al. Identification of virus-encoded microRNAs. Science (2004) 304:734–46. doi:10.1126/science.1096781
23. Cai X, Schäfer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 2:e23. doi:10.1371/journal.ppat.0020023
24. Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, Middeldorp J, et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol (2009) 83:2357–67. doi:10.1128/JVI.02104-08
25. Hutzinger R, Feederle R, Mrazek J, Schiefermeier N, Balwierz PJ, Zavolan M, et al. Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome. PLoS Pathog (2009) 5:e1000547. doi:10.1371/journal.ppat.1000547
26. Longnecker R, Kieff E, Cohen JI. Chapter 61. Epstein-Barr virus. 6th ed. In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B, editors. Fields Virology. (Vol. 2), Philadelphia, PA: Lippincott, Williams & Wilkins (2013). p. 1898–959.
27. Feederle R, Haar J, Bernhardt K, Linnstaedt SD, Bannert H, Lips H, et al. The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. J Virol (2011) 85:9801–10. doi:10.1128/JVI.05100-11
28. Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med (2015) 23(47):e132. doi:10.1038/emm.2014.82
29. Shair KH, Bendt KM, Edwards RH, Nielsen JN, Moore DT, Raab Traub N. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) and LMP2A function cooperatively to promote carcinoma development in a mouse carcinogenesis model. J Virol (2012) 86:5352–65. doi:10.1128/JVI.07035-11
30. Chen YP, Zhang WN, Chen L, Tang LL, Mao YP, Li WF, et al. Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis. Oncotarget (2015) 6(30):29311–23. doi:10.18632/oncotarget.4906
31. Ewelina G, Jacek R. Epstein-Barr virus–associated lymphomas. Semin Oncol (2015) 42:291–303. doi:10.1053/j.seminoncol.2014.12.030
32. Nicholson LJ, Hopwood P, Johannessen I, Salisbury JR, Codd J, Thorley Lawson D, et al. Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells. Oncogene (1997) 15:275–83. doi:10.1038/sj.onc.1201187
33. Kay KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A (1996) 93:11085–90. doi:10.1073/pnas.93.20.11085
34. Moshe Y, Jacques G. Oncogenes as Transcriptional Regulators: Cell Cycle Regulators and Chromosomal Translocation. (Vol. 2). Basel: Springer Basel AG (1997).
35. Ma X, Xu Z, Yang L, Xiao L, Tang M, Lu J, et al. EBV-LMP1-targeted DNAzyme induces DNA damage and causes cell cycle arrest in LMP1-positive nasopharyngeal carcinoma cells. Int J Oncol (2013) 43(5):1541–8. doi:10.3892/ijo.2013.2098
36. Liebowitz D, Wang D, Kieff E. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 58:233–7.
37. Gupta S, Termini JM, Niu L, Kanagavelu SK, Rahmberg AR, Kornbluth RS, et al. Latent membrane protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines. Retrovirology (2011) 8:39. doi:10.1186/1742-4690-8-39
38. Kaye KM, Izumi KM, Mosialos G, Kieff E. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation: fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol (1995) 69:675–83.
39. Huen DS, Henderson SA, Croom Carter D, Rowe M. The Epstein-Barr virus latent membrane protein (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxyl-terminal cytoplasmic domain. Oncogene (1995) 10:549–60.
40. Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus encoded latent membrane protein-1. Oncogene (1998) 16:1731–42. doi:10.1038/sj.onc.1201694
41. Eliopoulos AG, Gallagher NJ, Blake SM, Young LS. Activation of the p38 mitogen activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem (1999) 274:16085–96. doi:10.1074/jbc.274.23.16085
42. Yang L, Lu Z, Ma X, Cao Y, Sun LQ. A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBV LMP-1 gene. Molecules (2010) 15(9):6127–39. doi:10.3390/molecules15096127
43. Kang MS, Kieff E. Epstein-Barr virus latent genes. Exp Mol Med (2015) 23(47):e131. doi:10.1038/emm.2014.84
44. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J (1999) 18:3064–73. doi:10.1093/emboj/18.11.3064
45. Izumi KM, Kieff ED. The Epstein-Barr virus oncogenic product latent membrane protein 1 engages the tumour necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kB. Proc Natl Acad Sci U S A (1997) 94:125927. doi:10.1073/pnas.94.4.1447
46. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, et al. TRAF1, TRAF2, and TRAF3 effect NF-kB activation by an Epstein-Barr virus LMP1 domain important for B lymphocyte transformation. Mol Cell Biol (1996) 16:7098–108. doi:10.1128/MCB.16.12.7098
47. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumour necrosis factor receptor family. Cell (1995) 80:389–99. doi:10.1016/0092-8674(95)90489-1
48. Sandberg M, Hammerschmidt W, Sugden B. Characterisation of LMP1s association with TRAF1, TRAF2, and TRAF3. J Virol (1997) 71:4649–56.
49. Wang LW, Jiang S, Gewurz BE. Epstein-Barr virus LMP1-mediated oncogenicity. J Virol (2017) 91(21):e01718–16. doi:10.1128/JVI.01718-16
50. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C-terminus via a mechanism involving TRADD and TRAF2. J Virol (1999) 73:1023–35.
51. Bentz GL, Whitehurst CB, Pagano JS. Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9. J Virol (2011) 85(19):10144–53. doi:10.1128/JVI.05035-11
52. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J (1997) 16:6131–40. doi:10.1093/emboj/16.20.6131
53. Floettmann JE, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene (1997) 15:1851–8. doi:10.1038/sj.onc.1201359
54. Hatzivassilou E, Miller WE, Raab -Traub N, Kief E, Mosialos G. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor κB, and stress activated protein kinase. J Immunol (1998) 3:1116–21.
55. Horikawa T, Yang J, Kondo S, Yoshizaki T, Joab I, Furukawa M, et al. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res (2007) 67:1970–8. doi:10.1158/0008-5472.CAN-06-3933
56. Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A (2002) 99:10084–9. doi:10.1073/pnas.152059399
57. Wasil LR, Shair KHY. Epstein-Barr virus LMP1 induces focal adhesions and epithelial cell migration through effects on integrin-5 and N-cadherin. Oncogenesis (2015) 4:e171. doi:10.1038/oncsis.2015.31
58. Sides MD, Klingsberg RC, Shan B, Gordon KA, Nguyen HT, Lin Z, et al. The Epstein-Barr virus latent membrane protein 1 and transforming growth factor β1 synergistically induce epithelial—mesenchymal transition in lung epithelial cells. Am J Respir Cell Mol Biol (2011) 44:852–62. doi:10.1165/rcmb.2009-0232OC
59. Shair KHY, Schnegg CI, Raab Traub NEBV. Latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res (2008) 68:6997–7005. doi:10.1158/0008-5472.CAN-08-1178
60. Kondo S, Wakisaka N, Muramatsu M, Zen Y, Endo K, Murono S, et al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol (2011) 85:11255–64. doi:10.1128/JVI.00188-11
61. Zuo LL, Zhang J, Liu LZ, Zhou Q, Du SJ, Xin SY, et al. Cadherin 6 is activated by Epstein-Barr virus LMP1 to mediate EMT and metastasis as an interplay node of multiple pathways in nasopharyngeal carcinoma. Oncogenesis (2017) 6:402. doi:10.1038/s41389-017-0005-7
62. Morris MA, Laverick L, Wei W, Davis AM, O’Neill S, Wood L, et al. The EBV-encoded oncoprotein, LMP1, induces an epithelial-to-mesenchymal transition (EMT) via its CTAR1 domain through integrin-mediated ERK-MAPK signalling. Cancers (Basel) (2018) 10(5):E130. doi:10.3390/cancers10050130
63. Liu X, Li Y, Peng S, Yu X, Li W, Shi F, et al. Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination. Cell Death Dis (2018) 9(2):53. doi:10.1038/s41419-017-0081-9
64. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 66:2689–97.
65. Heussinger N, Buttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E, et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol (2004) 203:696–9. doi:10.1002/path.1569
66. Frech B, Zimber Strobl U, Suentzenich KO, Pavlish O, Lenoir GM, Bornkamm GW, et al. Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera. J Virol (1990) 64:2759–67.
67. Murray PG, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin’s disease. J Pathol (1992) 166:1–5. doi:10.1002/path.1711660102
68. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol (1997) 182:151–9. doi:10.1002/(SICI)1096-9896(199706)182:2<151::AID-PATH824>3.0.CO;2-3
69. Murray PG, Young LS. The Role of the Epstein-Barr virus in human disease. Front Biosci (2002) 7:d519–40. doi:10.2741/A792
70. Longnecker R, Miller CL, Miao XQ, Tomkinson B, Kieff E. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol (1993) 67:2006–13.
71. Longnecker R, Miller CL, Tomkinson B, Miao XQ, Kieff E. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol (1993) 67:5068–74.
72. Longan L, Longnecker R. Epstein-Barr virus latent membrane protein 2A has no growth-altering effects when expressed in differentiating epithelia. J Gen Virol (2000) 81:2245–52. doi:10.1099/0022-1317-81-9-2245
73. Scholle F, Bendt KM, Raab Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol (2000) 74:10681–9. doi:10.1128/JVI.74.22.10681-10689.2000
74. Manca C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood (2007) 110:3715–21. doi:10.1182/blood-2007-05-090142
75. Ikeda A, Merchant M, Lev L, Longnecker R, Ikeda M. Latent membrane protein 2A, a viral B cell receptor homologue, induces CD5+ B-1 cell development. J Immunol (2004) 172:5329–37. doi:10.4049/jimmunol.172.9.5329
76. Caldwell RG, Brown RC, Longnecker R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol (2000) 74:1101–13. doi:10.1128/JVI.74.3.1101-1113.2000
77. Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, et al. B cell receptor signal strength determines B cell fate. Nat Immunol (2004) 5:317–27. doi:10.1038/ni1036
78. Ikeda M, Ikeda A, Longan LC, Longnecker R. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology (2000) 268:178–91. doi:10.1006/viro.1999.0166
79. Dykstra ML, Longnecker R, Pierce SK. Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity (2001) 14:57–67. doi:10.1016/S1074-7613(01)00089-9
80. Fruehling S, Lee SK, Herrold R, Frech B, Laux G, Kremmer E, et al. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol (1996) 70:6216–26.
81. Fruehling S, Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology (1997) 235:241–51. doi:10.1006/viro.1997.8690
82. Winberg G, Matskova L, Chen F, Plant P, Rotin D, Gish G, et al. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol Cell Biol (2000) 20:8526–35. doi:10.1128/MCB.20.22.8526-8535.2000
83. Birdwell CE, Prasai K, Dykes S, Jia Y, Munroe TGC, Bienkowska-Haba M, et al. Epstein-Barr virus stably confers an invasive phenotype to epithelial cells through reprogramming of the WNT pathway. Oncotarget (2018) 9(12):10417–35. doi:10.18632/oncotarget.23824
84. Van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem (2002) 277:17901–5. doi:10.1074/jbc.M111635200
85. Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. The mitogen-activated protein kinase pathway in melanoma part I – activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer (2017) 73:85–92. doi:10.1016/j.ejca.2016.12.010
86. Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol (2015) 89(6):867–82. doi:10.1007/s00204-015-1472-2
87. Chen SY, Lu J, Shih YC, Tsai CH. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal regulated kinase. J Virol (2002) 76:9556–61. doi:10.1128/JVI.76.18.9556-9561.2002
88. Portis T, Longnecker R. Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J Virol (2003) 77:105–14. doi:10.1128/JVI.77.1.105-114.2003
89. Panousis CG, Rowe DT. Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase. J Virol (1997) 71:4752–60.
90. Anderson LJ, Longnecker R. EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. J Gen Virol (2008) 89:1563–8. doi:10.1099/vir.0.2008/001461-0
91. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta (1991) 1072:129–57.
92. Kovary K, Bravo R. Expression of different Jun and Fos proteins during the G0-to-G1 transition in mouse fibroblasts: in vitro and in vivo associations. Mol Cell Biol (1991) 11:2451–9. doi:10.1128/MCB.11.5.2451
93. Simons K, Ikonen E. Functional rafts in cell membranes. Nature (1997) 387:569–72. doi:10.1038/42408
94. Prochownik EV, Smith MJ, Snyder K, Emeagwali D. Amplified expression of three jun family members inhibits erythroleukemia differentiation. Blood (1990) 76:1830–7.
95. Su HY, Bos TJ, Monteclaro FS, Vogt PK. Jun inhibits myogenic differentiation. Oncogene (1991) 6:1759–66.
96. Schutte J, Viallet J, Nau M, Segal S, Fedorko J, Minna J. Jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell (1989) 59:987–97. doi:10.1016/0092-8674(89)90755-1
97. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature (1991) 354:494–6. doi:10.1038/354494a0
98. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 96:4240–5. doi:10.1073/pnas.96.8.4240
99. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (1997) 275:661–5. doi:10.1126/science.275.5300.661
100. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A (1994) 91:9131–5. doi:10.1073/pnas.91.19.9131
101. Khwaja A, Rodriguez Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J (1997) 16:2783–93. doi:10.1093/emboj/16.10.2783
102. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell (1997) 91:949–60. doi:10.1016/S0092-8674(00)80486-9
103. Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene (2004) 23:8619–28. doi:10.1038/sj.onc.1207905
104. Fukuda M, Ikuta K, Yanagihara K, Tajima M, Kuratsune H, Kurata T, et al. Effect of transforming growth factor-beta1 on the cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial cell lines. Virology (2001) 288:109–18. doi:10.1006/viro.2001.1071
105. Portis T, Ikeda M, Longnecker R. Epstein-Barr virus LMP2A: regulating cellular ubiquitination processes for maintenance of viral latency? Trends Immunol (2004) 25:422–6. doi:10.1016/j.it.2004.05.009
106. Fukuda M, Longnecker R. Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol (2004) 78:1697–705. doi:10.1128/JVI.78.4.1697-1705.2004
107. Inman GJ, Allday MJ. Apoptosis induced by TGF-beta 1 in Burkitt’s lymphoma cells is caspase 8 dependent but is death receptor independent. J Immunol (2000) 165:2500–10. doi:10.4049/jimmunol.165.5.2500
108. Ohta S, Yanagihara K, Nagata K. Mechanism of apoptotic cell death of human gastric carcinoma cells mediated by transforming growth factor beta. Biochem J (1997) 324(Pt 3):777–82. doi:10.1042/bj3240777
109. Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y. Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res (1998) 242:244–54. doi:10.1006/excr.1998.4096
110. Schrantz N, Blanchard DA, Auffredou MT, Sharma S, Leca G, Vazquez A. Role of caspases and possible involvement of retinoblastoma protein during TGFbeta-mediated apoptosis of human B lymphocytes. Oncogene (1999) 18:3511–9. doi:10.1038/sj.onc.1202718
111. Chen RH, Su YH, Chuang RL, Chang TY. Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene (1998) 17:1959–68. doi:10.1038/sj.onc.1202111
112. Grivennikov S, Karin M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2010) 21(1):11–9. doi:10.1016/j.cytogfr.2009.11.005
113. Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep (2015) 3(5):17663. doi:10.1038/srep17663
114. Nan J, Wang Y, Yang J, Stark GR. IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression. Proc Natl Acad Sci U S A (2018) 115(15):3906–11. doi:10.1073/pnas.1714102115
115. Stewart S, Dawson CW, Takada K, Curnow J, Moody CA, Sixbey JW, et al. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci U S A (2004) 101:15730–5. doi:10.1073/pnas.0402135101
116. Yan M, Zhang Y, He B, Xiang J, Wang ZF, Zheng FM. IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat Commun (2014) 17(5):3661. doi:10.1038/ncomms4661
117. Lieberman PM. Virology: Epstein-Barr virus turns 50. Science (2014) 343:1323–5. doi:10.1126/science.1252786
118. Lieberman PM. Keeping it quiet: chromatin control of gamma-herpesvirus latency. Nat Rev Microbiol (2013) 11:863–75. doi:10.1038/nrmicro3135
119. Cruickshank J, Shire K, Davidson AR, Edwards AM, Frappier L. Two domains of the Epstein-Barr virus origin DNA-binding protein, EBNA1, orchestrate sequence-specific DNA binding. J Biol Chem (2000) 275:22273–7. doi:10.1074/jbc.M001414200
120. Summers H, Barwell JA, Pfuetzner RA, Edwards AM, Frappier L. Cooperative assembly of EBNA1 on the Epstein-Barr virus latent origin of replication. J Virol (1996) 70:1228–31.
121. Thompson S, Messick T, Schultz DC, Reichman M, Lieberman PM. Development of a high636 throughput screen for inhibitors of Epstein-Barr virus EBNA1. J Biomol Screen (2010) 15:1107–15. doi:10.1177/1087057110379154
122. Cerimele F, Battle T, Lynch R, Frank DA, Murad E, Cohen C, et al. Reactive oxygen signalling and MAPK activation distinguish Epstein-Barr virus (EBV)-positive versus EBV-negative Burkitt’s lymphoma. Proc Natl Acad Sci U S A (2005) 102:175–9. doi:10.1073/pnas.0408381102
123. Cao JY, Mansouri S, Frappier L. Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses. J Virol (2012) 86:382–94. doi:10.1128/JVI.05648-11
124. Sivachandran N, Dawson CW, Young LS, Liu FF, Middeldorp J, Frappier L. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma. J Virol (2012) 86:60–8. doi:10.1128/JVI.05623-11
125. Frappier L. The Epstein-Barr virus EBNA1 protein. Scientifica (Cairo) (2012) 2012:438204. doi:10.6064/2012/438204
126. Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol (2000) 10:83–100. doi:10.1002/(SICI)1099-1654(200003/04)10:2<83::AID-RMV262>3.0.CO;2-T
127. Su W, Middleton T, Sugden B, Echols H. DNA looping between the origin of replication of Epstein-Barr virus and its enhancer site: stabilization of an origin complex with Epstein-Barr nuclear antigen 1. Proc Natl Acad Sci U S A (1991) 88:10870–4. doi:10.1073/pnas.88.23.10870
128. Frappier L, Goldsmith K, Bendell L. Stabilization of the EBNA1 protein on the Epstein-Barr virus latent origin of DNA replication by a DNA looping mechanism. J Biol Chem (1994) 269:1057–62.
129. Wood VH, O’Neil JD, Wei W, Stewart SE, Dawson CW, Young LS. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene (2007) 26:4135–47. doi:10.1038/sj.onc.1210496
130. Canaan A, Haviv I, Urban AE, Schulz VP, Hartman S, Zhang Z, et al. EBNA1 regulates cellular gene expression by binding cellular promoters. Proc Natl Acad Sci U S A (2009) 106:22421–6. doi:10.1073/pnas.0911676106
131. Dresang LR, Vereide DT, Sugden B. Identifying sites bound by Epstein-Barr virus nuclear antigen 1 (EBNA1) in the human genome: defining a position-weighted matrix to predict sites bound by EBNA1 in viral genomes. J Virol (2009) 83:2930–40. doi:10.1128/JVI.01974-08
132. Lu F, Wikramasinghe P, Norseen J, Tsai K, Wang P, Showe L, et al. Genome-wide analysis of host-chromosome binding sites for Epstein-Barr virus nuclear antigen 1 (EBNA1). Virol J (2010) 7:262. doi:10.1186/1743-422X-7-262
133. Tierney R, Nagra J, Hutchings I, Shannon Lowe C, Altmann M, Hammerschmidt W, et al. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth transforming program. J Virol (2007) 81:10092–100. doi:10.1128/JVI.00358-07
134. Hofelmayr H, Strobl LJ, Marschall G, Bornkamm GW, Zimber Strobl U. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J Virol (2001) 75:2033–40. doi:10.1128/JVI.75.5.2033-2040.2001
135. Strobl LJ, Hofelmayr H, Marschall G, Brielmeier M, Bornkamm GW, Zimber Strobl U. Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J Virol (2000) 74:1727–35. doi:10.1128/JVI.74.4.1727-1735.2000
136. Sakai T, Taniguchi Y, Tamura K, Minoguchi S, Fukuhara T, Strobl LJ, et al. Functional replacement of the intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2. J Virol (1998) 72:6034–9.
137. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A (1994) 91:7568–72. doi:10.1073/pnas.91.16.7568
138. Yalamanchili R, Tong X, Grossman S, Johannsen E, Mosialos G, Kieff E. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology (1994) 204:634–41. doi:10.1006/viro.1994.1578
139. Zimber Strobl U, Strobl LJ, Meitinger C, Hinrichs R, Sakai T, Furukawa T, et al. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila suppressor of hairless. EMBO J (1994) 13:4973–82.
140. Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science (1994) 265:92–5. doi:10.1126/science.8016657
141. Lee JM, Lee KH, Weidner M, Osborne BA, Hayward SD. Epstein-Barr virus EBNA2 blocksNur77-mediated apoptosis. Proc Natl Acad Sci U S A (2002) 99:11878–83. doi:10.1073/pnas.182552499
142. Lee JM, Lee KH, Farrell CJ, Ling PD, Kempkes B, Park JH, et al. EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J Virol (2004) 78:12694–7. doi:10.1128/JVI.78.22.12694-12697.2004
143. Godoi PH, Wilkie Grantham RP, Hishiki A, Sano R, Matsuzawa Y, Yanagi H, et al. Orphan nuclear receptor NR4A1 binds a novel protein interaction site on anti-apoptotic B cell lymphoma gene 2 family proteins. J Biol Chem (2016) 291:14072–84. doi:10.1074/jbc.M116.715235
144. Campion EM, Hakimjavadi R, Loughran ST, Phelan S, Smith SM, D’Souza BN, et al. Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor beta1-induced B-cell apoptosis. J Virol (2014) 88:5001–13. doi:10.1128/JVI.03642-13
145. Pegman PM, Smith SM, D’Souza BN, Loughran ST, Maier S, Kempkes B, et al. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. J Virol (2006) 80:8133–44. doi:10.1128/JVI.00278-06
146. Wood CD, Veenstra H, Khasnis S, Gunnell A, Webb HM, Shannon-Lowe C, et al. MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. Elife (2016) 5:e18270. doi:10.7554/eLife.18270
147. Dejure FR, Eilers M. MYC and tumor metabolism: chicken and egg. EMBO J (2017) 36(23):3409–20. doi:10.15252/embj.201796438
148. Sinclair AJ, Palmero I, Peters G, Farrell PJ. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J (1994) 13:3321–8.
149. Tierney RJ, Kao KY, Nagra JK, Rickinson AB. Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J Virol (2011) 85:12362–75. doi:10.1128/JVI.06059-11
150. Kashuba E, Yurchenko M, Szirak K, Stahl J, Klein G, Szekely L. Epstein-Barr virus-encoded EBNA-5 binds to Epstein-Barr virus-induced Fte1/S3a protein. Exp Cell Res (2005) 303(1):47–55. doi:10.1016/j.yexcr.2004.08.025
151. Kashuba E, Mattsson K, Pokrovskaja K, Kiss C, Protopopova M, Ehlin Henriksson B, et al. EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells. Int J Cancer (2003) 105:644–53. doi:10.1002/ijc.11124
152. Allday MJ, Bazot Q, White RE. The EBNA3 family: two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells. Curr Top Microbiol Immunol (2015) 391:61–117. doi:10.1007/978-3-319-22834-1_3
153. Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M. The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology (1994) 205:596–602. doi:10.1006/viro.1994.1687
154. Yenamandra SP, Sompallae R, Klein G, Kashuba E. Comparative analysis of the Epstein-Barr virus encoded nuclear proteins of EBNA-3 family. Comput Biol Med (2009) 39:1036–42. doi:10.1016/j.compbiomed.2009.08.006
155. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, Lang R, et al. Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog (2009) 5:e1000506. doi:10.1371/journal.ppat.1000506
156. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog (2010) 6:e1000951. doi:10.1371/journal.ppat.1000951
157. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 67:2014–25.
158. Tomkinson B, Kieff E. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol (1992) 66:2893–903.
159. Chen A, Divisconte M, Jiang X, Quink C, Wang F. Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol (2005) 79:4506–9. doi:10.1128/JVI.79.7.4506-4509.2005
160. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A (2011) 108:1919–24. doi:10.1073/pnas.1019599108
161. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, Takada K. Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A (2006) 103:19500–5. doi:10.1073/pnas.0604919104
162. Skalska L, White RE, Parker GA, Turro E, Sinclair AJ, Paschos K, et al. Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog (2013) 9:e1003187. doi:10.1371/journal.ppat.1003187
163. Jiang S, Willox B, Zhou H, Holthaus AM, Wang A, Shi TT, et al. Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci U S A (2014) 111:421–6. doi:10.1073/pnas.1321704111
164. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt’s lymphoma. Oncogene (2008) 27:421–33. doi:10.1038/sj.onc.1210668
165. Cai Q, Guo Y, Xiao B, Banerjee S, Saha A, Lu J, et al. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog (2011) 7:e1002418. doi:10.1371/journal.ppat.1002418
166. Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, et al. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology (2009) 388:236–47. doi:10.1016/j.virol.2009.03.027
167. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. Epstein-Barr virus nuclear antigen 3C ugments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol (2009) 83:4652–69. doi:10.1128/JVI.02408-08
168. McClellan MJ, Wood CD, Ojeniyi O, Cooper TJ, Kanhere A, Arvey A, et al. Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathog (2013) 9:e1003636. doi:10.1371/journal.ppat.1003636
169. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ. BIM promoter directly targetedby EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res (2012) 40:7233–46. doi:10.1093/nar/gks391
Keywords: Burkitt’s lymphoma, nasopharyngeal carcinoma, B-cells lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, oncoproteins, oncogenes
Citation: El-Sharkawy A, Al Zaidan L and Malki A (2018) Epstein–Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis. Front. Oncol. 8:265. doi: 10.3389/fonc.2018.00265
Received: 31 March 2018; Accepted: 27 June 2018;
Published: 02 August 2018
Edited by:
Ali A. Sultan, Weill Cornell Medicine-Qatar, QatarReviewed by:
Muntaser Eltayeb Ibrahim, University of Khartoum, SudanAga Syed Sameer, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia
Randa Chkir Ghedira, University of Monastir, Tunisia
Copyright: © 2018 El-Sharkawy, Al Zaidan and Malki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ahmed Malki, YWhtZWQubWFsa2kmI3gwMDA0MDtxdS5lZHUucWE=